Multiple Myeloma Experience Survey - Teclistamab (TECVAYLI ) |
Introduction
We need your help!
Myeloma Canada is seeking information from people affected by multiple myeloma regarding a new indication for teclistamab (TECVAYLI), soon undergoing reimbursement review at Canada’s Drug Agency (CDA) and l'Institut national d’excellence en santé et en services sociaux (INESSS).
Sharing your experience can help decision-makers better understand how this treatment could benefit Canadians with myeloma.
This survey is intended for:
- Adults living with multiple myeloma and their care partners who have received 1 - 3 prior lines of therapy including lenalidomide and an anti-CD38 monoclonal antibody.
AND
- Patients who have received or are currently receiving treatment with teclistamab monotherapy and their care partners.
As always, patient and caregiver input is particularly important, and your participation can contribute to increasing Canadians' access to new myeloma treatments.
This survey should only take around 10 minutes of your time. We ask that the survey please be completed by November 16th, 2026, 11:59 PM EST.
If you have any questions, please write to contact@myeloma.ca and indicate “Treatment Survey” in the subject line.
Thank you in advance for your participation and helping your fellow Canadians impacted by myeloma!
Privacy policy: All survey datum is collected by Myeloma Canada. To ensure patient and caregiver privacy and confidentiality, individual responses will not be identifiable. Please note selected quotations may be used in the final report without reference to any identifying information.
If you have any questions, please write to contact@myeloma.ca and indicate “Treatment Survey” in the subject line.
Thank you in advance for your participation and helping your fellow Canadians impacted by myeloma!
Privacy policy: All survey datum is collected by Myeloma Canada. To ensure patient and caregiver privacy and confidentiality, individual responses will not be identifiable. Please note selected quotations may be used in the final report without reference to any identifying information.